

Ketamine Interest Group

Meeting Minutes

Thursday, September 17th, 2020 @ 2:00pm ET

Co-Chairs:	Mark Niciu (Iowa), Adam Kaplin (JHMI)
Attendees:	Jonathan Cole (Cincinnati), Srinath Gopinath (Florida), Sagar Parikh (Michigan), Jennifer Vande Voort (Mayo)
Regrets:	Paula Bolton (McLean), Ray DePaulo (JHMI), Robert Meisner (McLean), Christopher Schneck (CU Anschutz)
NNDC:	Diana Burnett

1. **NNDC Portal** – Access and training will be added to the October agenda. The portal will be used for sharing billing information, policies, protocols, etc.
2. **Site Ketamine Survey** – Results were reviewed in full and the audio recording is available for review via email link from Diana.
 - a. Dr. Parikh shared 3 papers relating to IV ketamine and substance use disorders (see attached: Dakwar et al., Das et al., Ezquerra-Romano et al.)
 - b. COVID-19 pandemic impacts on ketamine clinical services (Question #28) – to be summarized in a letter to the editor, manuscript, or other - all contributors as authors
 - ASCP (<https://ascpp.org/ascp-meetings/ascp-annual-meeting/>)
 - SOBP (<https://sobp.org/meetings/2021-sobp-annual-meeting/>)
 - JAD
3. **Collaborative Study Ideas (with funding)** – Topic to be included on October agenda
 - a. The majority of JHU coronavirus patients are administered propofol, ketamine or both for sedation. There is at least the nucleus of a database for a study on whether this had an impact on their inflammatory markers. (A. Kaplin)
 - b. Might there be a PCORI (or other) grant with a maintenance design that this group could aspire to, similar to the NNDC efforts that led to the GenECT and Bio-K studies? (S. Parikh)
 - c. Ketamine tied to COVID-19 will be the way to bring in funding. (J. Vande Voort)
 - d. There is a PLOS One paper in process reporting that the COVID-19 virus is temperature sensitive. (A. Kaplin)
 - e. Dr. Niciu shared 2 papers related to PET studies at Yale (see attached: Esterlis et al. and Holmes et al.)

Next Meeting: Thursday, October 15th, 2020 @ 2pm ET